

Large international order for Zenicor - the world's largest screening project for atrial fibrillation

Stockholm, May 16, 2018

Zenicor Medical Systems AB (publ) announces today that the company has been chosen as sole supplier to a screening project for atrial fibrillation in Great Britain. The project is the largest long-term screening project with the aim to prevent stroke in the world to date, and the largest single deal in the 15 year history of Zenicor. The total value of the deal is ca 7 MSEK. In total, 300 GP offices will take part in the project.

- *It is very pleasing that Zenicor has been chosen in fierce competition with all the international players in the market. The project confirms Zenicor-ECG as the primary method of screening for atrial fibrillation, "said Zenicor's CEO Mats Palerius.*

The purpose of the project is to investigate whether screening for atrial fibrillation prevents stroke and other problems in comparison to current routine care and if it is cost effective. The project is being conducted by Cambridge University in the UK and funded by the NIHR, National Institute for Health Research. The screening project is scheduled to commence in the summer of 2018 and will last until 2021. Over 300 GP offices in England will participate and the total number of participants will be 120,000 (between 65-84 years), of whom 40,000 will be invited to screen with Zenicor ECG and 80,000 will serve as a control group.

The project is headed by Prof. Jonathan Mant, investigator in both primary care and stroke prevention. Mant and his research team led, among other things, the groundbreaking SAFE study (2005), the to date largest primary care-based study for screening and treatment of atrial fibrillation. Prof. Jonathan Mant is head of the National Institute of Health Research Primary Care Unit at the University of Cambridge.

Prof. Jonathan Mant comments:

– We needed a system that is simple to use that is able to record an ECG of high diagnostic quality and that can manage large amounts of ECGs and patients. Zenicor is one of few systems fulfilling these requirements. This, in combination with the knowledge that this system has already successfully been used in large studies made Zenicor an obvious choice for our research.

For more information, please read the press release from Cambridge published May 16th, 2018 <http://www.phpc.cam.ac.uk/pcu/nih-awards-3m-for-new-research-to-investigate-screening-to-prevent-one-in-ten-strokes/>

About atrial fibrillation and screening for atrial fibrillation

- The risk of stroke is greatly increased in those who have atrial fibrillation. With proper treatment, the risk reduces by about 70 percent.
- Risk factors for both stroke and atrial fibrillation include high age (over 65 years), cardiovascular disease, diabetes and previous stroke.
- According to previous research with Zenicor-ECG, atrial fibrillation screening detects atrial fibrillation in approximately 3 percent of the examined group. People who would otherwise have been without anti-stroke treatment.

About NIHR

The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research. Established by the Department of Health and Social Care, the NIHR:

- funds high quality research to improve health
- trains and supports health researchers
- provides world-class research facilities
- works with the life sciences industry and charities to benefit all
- involves patients and the public at every step

For further information, visit the NIHR website (www.nihr.ac.uk).

About the NHS

The National Health Service (NHS) is the governmental organization responsible for public health care in the UK. NHS finances primary and specialist care, and all residents are entitled to free health care through the NHS. In the UK, primary care units, General Practitioners, play a key role in guiding and responsible for patient health in their local area.

About Zenicor and thumb-ECG from Zenicor

Zenicor Medical Systems is a leading company in arrhythmia and stroke prevention. Zenicor's ECG is a system optimized for cardiac arrhythmia diagnosis, including atrial fibrillation in the healthcare industry, and today it is used in over 400 clinics in ten countries in Europe. The efficiency of the solution has been documented in a number of studies and articles in internationally leading scientific journals. These studies have shown that Zenicor's ECG has a superior diagnostic ability, combined with cost-effectiveness and ease of use compared to traditional methods.

For further information, please contact:

Mats Palerius, CEO, Zenicor Medical Systems AB,

Phone: +46 70 561 55 64

E-mail: mats@zenicor.se

High resolution images of Zenicor ECG are available for download:

<https://zenicor.com/press-material/>

D This information is such information as Zenicor is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on May 16, 2018.